INHALE-1: A 26-week Primary Treatment Phase,with 26-week Extension, Open-label, RandomizedClinical Trial Evaluating the Efficacy and Safety ofAfrezza?? Versus Rapid-acting Insulin AnalogInjections, Both in Combination with a Basal Insulin,in Pediat

Project: Research project

Project Details

Description

INHALE-1: A 26-week Primary Treatment Phase, with 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza?? Versus Rapid-acting Insulin Analog Injections, Both in Combination with a Basal Insulin, in Pediat
StatusActive
Effective start/end date3/20/23 → 6/30/27

Funding

  • JAEB CENTER FOR HEALTH RESEARCH
  • MANNKIND CORP

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint